Modeling of Causes of Sina Weibo Continuance Intention with Mediation of Gender Effects

Sina Weibo is a Twitter-like social networking site and one of the most popular microblogging services in China. This study aims to examine the factors that influence the intentions of users to continue using this site. This paper synthesizes the expectation confirmation model (ECM), constructs of habit and perceived critical mass, and the gender effect to construct a theoretical model to explain and predict these user intentions. The model is then tested via an online survey of 498 Sina Weibo users and partial least squares (PLS) modeling. The results indicate that the continuance intention of users is directly predicted by their perceived usefulness of the service (β=0.299), their satisfaction (β=0.208), and their habits (β=0.389), which jointly explain 65.9% of the variance in intention. In addition to the effects of these predictors on the continuance intentions of Sina Weibo users, an assessment of the moderating effect of gender suggests that habit plays a more important role for females than for males in continuance intention, but perceived usefulness seems to be more important for males than for females. The implications of these findings are then discussed

Robust information hiding in low-resolution videos with quantization index modulation in DCT-CS domain

Video information hiding and transmission over noisy channels leads to errors on video and degradation of the visual quality notably. In this paper, a video signal fusion scheme is proposed to combine sensed host signal and the hidden signal with quantization index modulation (QIM) technology in the compressive sensing (CS) and discrete cosine transform (DCT) domain. With quantization based signal fusion, a realistic solution is provided to the receiver, which can improve the reconstruction video quality without requiring significant extra channel resource. The extensive experiments have shown that the proposed scheme can effectively achieve the better trade-off between robustness and statistical invisibility for video information hiding communication. This will be extremely important for low-resolution video analytics and protection in big data era

Euryale Ferox Seed-inspired Super-lubricated Nanoparticles for Treatment of Osteoarthritis

Osteoarthritis has been regarded as a typical lubrication deficiency related joint disease, which is characterized by the breakdown of articular cartilage at the joint surface and the inflammation of the joint capsule. Here, inspired by the structure of the fresh euryale ferox seed that possesses a slippery aril and a hard coat containing starchy kernel, a novel superlubricated nanoparticle, namely poly (3‐sulfopropyl methacrylate potassium salt)‐grafted mesoporous silica nanoparticles (MSNs‐NH2@PSPMK), is biomimicked and synthesized via a one‐step photopolymerization method. The nanoparticles are endowed with enhanced lubrication by the grafted PSPMK polyelectrolyte polymer due to the formation of tenacious hydration layers surrounding the negative charges, and simultaneously are featured with effective drug loading and release behavior as a result of the sufficient mesoporous channels in the MSNs. When encapsulated with an anti‐inflammatory drug diclofenac sodium (DS), the lubrication capability of the superlubricated nanoparticles is improved, while the drug release rate is sustained by increasing the thickness of PSPMK layer, which is simply achieved via adjustment of the precursor monomer concentration in the photopolymerization process. Additionally, the in vitro and in vivo experimental results show that the DS‐loaded MSNs‐NH2@PSPMK nanoparticles effectively protect the chondrocytes from degeneration, and thus, inhibit the development of osteoarthritis.Peer reviewe

Tirofiban for Stroke without Large or Medium-Sized Vessel Occlusion

The effects of the glycoprotein IIb/IIIa receptor inhibitor tirofiban in patients with acute ischemic stroke but who have no evidence of complete occlusion of large or medium-sized vessels have not been extensively studied. In a multicenter trial in China, we enrolled patients with ischemic stroke without occlusion of large or medium-sized vessels and with a National Institutes of Health Stroke Scale score of 5 or more and at least one moderately to severely weak limb. Eligible patients had any of four clinical presentations: ineligible for thrombolysis or thrombectomy and within 24 hours after the patient was last known to be well; progression of stroke symptoms 24 to 96 hours after onset; early neurologic deterioration after thrombolysis; or thrombolysis with no improvement at 4 to 24 hours. Patients were assigned to receive intravenous tirofiban (plus oral placebo) or oral aspirin (100 mg per day, plus intravenous placebo) for 2 days; all patients then received oral aspirin until day 90. The primary efficacy end point was an excellent outcome, defined as a score of 0 or 1 on the modified Rankin scale (range, 0 [no symptoms] to 6 [death]) at 90 days. Secondary end points included functional independence at 90 days and a quality-of-life score. The primary safety end points were death and symptomatic intracranial hemorrhage. A total of 606 patients were assigned to the tirofiban group and 571 to the aspirin group. Most patients had small infarctions that were presumed to be atherosclerotic. The percentage of patients with a score of 0 or 1 on the modified Rankin scale at 90 days was 29.1% with tirofiban and 22.2% with aspirin (adjusted risk ratio, 1.26; 95% confidence interval, 1.04 to 1.53, P = 0.02). Results for secondary end points were generally not consistent with the results of the primary analysis. Mortality was similar in the two groups. The incidence of symptomatic intracranial hemorrhage was 1.0% in the tirofiban group and 0% in the aspirin group. In this trial involving heterogeneous groups of patients with stroke of recent onset or progression of stroke symptoms and nonoccluded large and medium-sized cerebral vessels, intravenous tirofiban was associated with a greater likelihood of an excellent outcome than low-dose aspirin. Incidences of intracranial hemorrhages were low but slightly higher with tirofiban

Methylprednisolone as Adjunct to Endovascular Thrombectomy for Large-Vessel Occlusion Stroke

Importance It is uncertain whether intravenous methylprednisolone improves outcomes for patients with acute ischemic stroke due to large-vessel occlusion (LVO) undergoing endovascular thrombectomy. Objective To assess the efficacy and adverse events of adjunctive intravenous low-dose methylprednisolone to endovascular thrombectomy for acute ischemic stroke secondary to LVO. Design, Setting, and Participants This investigator-initiated, randomized, double-blind, placebo-controlled trial was implemented at 82 hospitals in China, enrolling 1680 patients with stroke and proximal intracranial LVO presenting within 24 hours of time last known to be well. Recruitment took place between February 9, 2022, and June 30, 2023, with a final follow-up on September 30, 2023.InterventionsEligible patients were randomly assigned to intravenous methylprednisolone (n = 839) at 2 mg/kg/d or placebo (n = 841) for 3 days adjunctive to endovascular thrombectomy. Main Outcomes and Measures The primary efficacy outcome was disability level at 90 days as measured by the overall distribution of the modified Rankin Scale scores (range, 0 [no symptoms] to 6 [death]). The primary safety outcomes included mortality at 90 days and the incidence of symptomatic intracranial hemorrhage within 48 hours. Results Among 1680 patients randomized (median age, 69 years; 727 female [43.3%]), 1673 (99.6%) completed the trial. The median 90-day modified Rankin Scale score was 3 (IQR, 1-5) in the methylprednisolone group vs 3 (IQR, 1-6) in the placebo group (adjusted generalized odds ratio for a lower level of disability, 1.10 [95% CI, 0.96-1.25]; P = .17). In the methylprednisolone group, there was a lower mortality rate (23.2% vs 28.5%; adjusted risk ratio, 0.84 [95% CI, 0.71-0.98]; P = .03) and a lower rate of symptomatic intracranial hemorrhage (8.6% vs 11.7%; adjusted risk ratio, 0.74 [95% CI, 0.55-0.99]; P = .04) compared with placebo. Conclusions and Relevance Among patients with acute ischemic stroke due to LVO undergoing endovascular thrombectomy, adjunctive methylprednisolone added to endovascular thrombectomy did not significantly improve the degree of overall disability.Trial RegistrationChiCTR.org.cn Identifier: ChiCTR210005172